摘要
目的研究急性冠状动脉综合征(ACS)患者早期应用较大剂量阿托伐他汀治疗对抑制动脉粥样硬化斑块细胞外基质降解、减少炎症反应和稳定斑块的作用。方法58例ACS患者随机分为对照组(28例,未服用任何调脂药物)和阿托伐他汀组(30例,20mg/d),测定治疗前后金属蛋白酶-9(MMP-9)、C反应蛋白(CRP)和血脂水平的变化。结果两组治疗前、后血脂各组成分的变化差异均无统计学意义(P>0.05),而阿托伐他汀治疗组治疗后MMP-9及CRP水平均明显降低,与治疗前比较差异有统计学意义(P<0.01)。结论ACS患者早期应用大剂量他汀类药物治疗,可减少斑块基质成分的降解和炎症反应,具有稳定斑块作用。
Objective To investigate the influence of early atorvastatin on matrix metalloproteinase-9 （MMP-9） and e-reactive protein （CRP） levels in patients acute coronary syndrome （ACS）. Methods 58 patients of ACS were stratified by randomized, eontrastive assigned to atarvastatin group （20 mg/d of atorvastatin for 3 days,n=30）, or to the control group （no lipid-lowering drugs,n=28）. The serum levels of MMP-9, CRP before and after treatment were detected. Results Levels of plasma lipid were not changed before and after treatment in both groups. Levels of serum MMP-9 and CRP in the atorvastatin treatment group significantly decreased（P〈0.01 ）. There were no relations between the decrease percent of TC and LDL-C and that of MMP-9 and CRP. Condusion Atorvastatin decreased plasma levels of inflammatory factors in the patients acute coronary syndrome, so it may benefit to olaoue stabilization.
出处
《中国心血管病研究》
CAS
2008年第10期735-737,共3页
Chinese Journal of Cardiovascular Research
